var data={"title":"Keratoacanthoma: Epidemiology, risk factors, and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Keratoacanthoma: Epidemiology, risk factors, and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Jerry D Brewer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">June K Robinson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 20, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H5186444\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Keratoacanthoma (KA) is a cutaneous tumor that most commonly presents as a dome-shaped nodule with a central keratin-filled crater (<a href=\"image.htm?imageKey=DERM%2F55042%7EDERM%2F81629%7EDERM%2F59593%7EDERM%2F73408%7EDERM%2F52368\" class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \">picture 1A-E</a>) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. KA most frequently develops on hair-bearing, sun-exposed skin. Middle-aged and elderly adults with fair complexions are most frequently affected [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2\" class=\"abstract_t\">2</a>]. </p><p>A distinguishing feature of KA is a clinical course characterized by rapid initial growth followed by a variable period of lesion stability and subsequent spontaneous resolution [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2\" class=\"abstract_t\">2</a>]. The recognition of this unique characteristic in a tumor with clinical and histopathologic features that closely resemble cutaneous squamous cell carcinoma has led to significant debate over the classification of this lesion.</p><p>The epidemiology, risk factors, and diagnosis of KA will be discussed here. The management and prognosis of KA is reviewed separately. (See <a href=\"topic.htm?path=keratoacanthoma-management-and-prognosis\" class=\"medical medical_review\">&quot;Keratoacanthoma: Management and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5186451\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although KA is a common tumor, the potential for spontaneous resolution, the variability in documentation of lesions as KA or squamous cell carcinoma, and the relative paucity of epidemiological studies performed on this disease hinder definitive conclusions on tumor incidence. The vast majority of reported cases of KA have occurred in fair-skinned individuals [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"#H1923380\" class=\"local\">'Risk factors'</a> below.)</p><p>KA can occur at any age, and may present as a solitary lesion (the most common presentation) or infrequently in the context of specific disorders associated with multiple KAs [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/4-7\" class=\"abstract_t\">4-7</a>] (see <a href=\"#H2295938\" class=\"local\">'Multiple keratoacanthomas'</a> below). Solitary KA has a peak incidence between the ages of 50 and 69 [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2\" class=\"abstract_t\">2</a>]; rarely, lesions develop in individuals under the age of 20 [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>]. Data on the distribution of KA among the sexes vary. Estimates of the sex ratio range from a similar incidence in both sexes to a three times greater risk for KA among males [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/3,8,9\" class=\"abstract_t\">3,8,9</a>]. </p><p>It is unclear whether the incidence of KA is subject to seasonal variation in temperate climates. A retrospective study at a medical center in Rhode Island that analyzed patient data obtained between 1990 and 1992 found that more lesions were diagnosed in the summer months than in the winter (incidence ratio 1.38:1) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. However, retrospective studies in Minnesota and Texas have failed to confirm these findings [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H1923751\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of KA is poorly understood. It is generally accepted that KA is most likely derived from the follicular infundibulum [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/11\" class=\"abstract_t\">11</a>]. However, the mechanisms behind the characteristic phenomenon of rapid lesion growth followed by spontaneous resolution are not well defined. Based upon the available data, changes in the expression of genes and proteins involved in epidermal cell proliferation, cell adhesion, and cell survival may play significant roles in lesion development. Proposed contributors to lesion regression include the upregulation of factors that promote apoptosis, events related to normal cycling of the hair follicle, and activation of an immunologic response against the tumor [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. &#160;</p><p>Examples of specific factors identified as potentially relevant in the life cycle of KA include the homeodomain interacting protein kinase 2 (HIPK2) gene (a regulator of cell cycling and apoptosis) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/13\" class=\"abstract_t\">13</a>], the p53 tumor suppressor protein [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/14\" class=\"abstract_t\">14</a>], the H-ras proto-oncogene [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/15,16\" class=\"abstract_t\">15,16</a>], the adhesion molecules beta-catenin and CD44 [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/17\" class=\"abstract_t\">17</a>], and levels of the bcl-2 apoptosis regulatory protein and Bak proapoptotic protein [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/14,18-20\" class=\"abstract_t\">14,18-20</a>]. Additional potential contributors include granzyme B, a serine protease expressed by cytotoxic T cells and natural killer cells that promotes apoptosis [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/21\" class=\"abstract_t\">21</a>], and p27 (kip), an inhibitor of cyclin dependent kinases that may promote lesion regression [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/22\" class=\"abstract_t\">22</a>]. Further study is necessary to clarify the mechanisms involved in the development and involution of KA.</p><p class=\"headingAnchor\" id=\"H1923197\"><span class=\"h1\">RELATIONSHIP WITH SQUAMOUS CELL CARCINOMA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The relationship between KA and squamous cell carcinoma is controversial [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2,23\" class=\"abstract_t\">2,23</a>]. While some authors perceive KA as a distinct follicular-based squamous proliferation that usually follows a benign clinical course [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/24-28\" class=\"abstract_t\">24-28</a>], others counter that KA is actually a clinical variant of cutaneous squamous cell carcinoma prone to spontaneous regression and occasional aggressive behavior and metastasis [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/5,29-31\" class=\"abstract_t\">5,29-31</a>]. Dissolution of this controversy is hampered by the lack of histopathologic criteria that definitively differentiate KA and squamous cell carcinoma [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/32\" class=\"abstract_t\">32</a>]. Reports documenting transformation of KA to squamous cell carcinoma also raise questions about whether these lesions represent a continuum of a single disease rather than distinct entities [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/27,33,34\" class=\"abstract_t\">27,33,34</a>]. (See <a href=\"#H256623\" class=\"local\">'Differentiation from SCC'</a> below and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-cutaneous-squamous-cell-carcinoma-scc\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1923380\"><span class=\"h1\">RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of factors may influence the likelihood that an individual will develop KA [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. Examples include skin pigmentation; exposure to ultraviolet radiation trauma, chemical carcinogens, or certain medications; and genetic abnormalities. These factors are discussed in greater detail below.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Skin color </strong>&ndash; The risk for KA decreases with increasing skin pigmentation [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2,9,35\" class=\"abstract_t\">2,9,35</a>]. Among 22,000 patients seen at a specialized surgical skin cancer practice in Houston, Texas between 1998 and 2006, all 234 patients with KA were Caucasian with Fitzpatrick skin phototypes I, II, or III (<a href=\"image.htm?imageKey=PC%2F60541\" class=\"graphic graphic_table graphicRef60541 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/3\" class=\"abstract_t\">3</a>]. In addition, the differences in disease incidence reported in the late 20<sup>th</sup> century in the predominantly fair-skinned population of Australia (150 per 100,000 individuals), Japanese-Hawaiians (22 per 100,000 individuals), and Filipinos in Hawaii (7 per 100,000 individuals) also lend support to an important role for skin type [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/36-38\" class=\"abstract_t\">36-38</a>]. KA is rare among individuals with deeply pigmented skin [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Ultraviolet radiation </strong>&ndash;<strong> </strong>Although human studies that definitively link exposure to ultraviolet radiation to the development of KA are lacking, the observation that KA most frequently occurs on sun-exposed skin and in fair-skinned individuals supports a role for ultraviolet radiation as a contributing factor [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>]. Moreover, high numbers of treatments with psoralen plus ultraviolet A (PUVA) phototherapy have been linked to an increased risk for KA. In a retrospective study of approximately 500 patients with psoriasis who were treated with PUVA, patients who received high cumulative doses of PUVA were significantly more likely to develop KA than those who received lesser amounts of PUVA therapy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/39\" class=\"abstract_t\">39</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Trauma </strong>&ndash; Infrequently, KA develops in sites of iatrogenic (eg, surgery, laser therapy, cryotherapy) or accidental trauma [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/40-48\" class=\"abstract_t\">40-48</a>]. Although most reported cases of trauma-induced KA have occurred in adults, this phenomenon has also been documented in an adolescent [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/41\" class=\"abstract_t\">41</a>]. Post-surgical KA usually appears one to three months after surgery [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/42-44\" class=\"abstract_t\">42-44</a>]. Treatment with ionizing radiation has also been linked with the development of multiple KAs in a patient with multiple self-healing squamous epithelioma (MSSE, also known as Ferguson-Smith disease) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/49\" class=\"abstract_t\">49</a>]. (See <a href=\"#H2295938\" class=\"local\">'Multiple keratoacanthomas'</a> below.)</p><p/><p class=\"bulletIndent1\">The explanation for the development of KA at sites of trauma is unknown. Some authors have speculated that in skin previously exposed to carcinogens such as ultraviolet radiation, factors associated with the wound-healing response may promote the development of these tumors [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/23\" class=\"abstract_t\">23</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Genetics </strong>&ndash; Several genetic syndromes are associated with KA, including the variant of Lynch syndrome known as Muir-Torre syndrome, xeroderma pigmentosum, and MSSE. Muir-Torre syndrome may present with KA, sebaceous tumors, and visceral malignancy. In this syndrome, tumor formation occurs as a result of germline mutations in DNA mismatch repair genes.</p><p/><p class=\"bulletIndent1\">KAs may develop early in life in both xeroderma pigmentosum and MSSE. Xeroderma pigmentosum is an autosomal recessive syndrome associated with defects in DNA repair [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/50-52\" class=\"abstract_t\">50-52</a>]. In contrast, MSSE is an autosomal dominant disorder associated with loss-of-function mutations in the transforming growth factor beta receptor 1 gene (TGFBR1 or ALK5) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"topic.htm?path=the-genodermatoses#H523750964\" class=\"medical medical_review\">&quot;The genodermatoses&quot;, section on 'Xeroderma pigmentosum'</a> and <a href=\"topic.htm?path=muir-torre-syndrome\" class=\"medical medical_review\">&quot;Muir-Torre syndrome&quot;</a> and <a href=\"#H2295938\" class=\"local\">'Multiple keratoacanthomas'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Drug exposure </strong>&ndash;<strong> </strong>BRAF inhibitors (eg, <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">vemurafenib</a>, <a href=\"topic.htm?path=dabrafenib-drug-information\" class=\"drug drug_general\">dabrafenib</a>) are molecularly targeted agents used in the treatment of multiple malignancies. The development of KA or cutaneous squamous cell carcinoma is a potential adverse effect of these therapies [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/54,55\" class=\"abstract_t\">54,55</a>]. A paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway resulting the proliferation and survival of abnormal cells may contribute to the occurrence of these lesions [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/56\" class=\"abstract_t\">56</a>]. Additional agents that have been associated with the development of KA include <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>, a tyrosine kinase inhibitor used in the treatment of cancer [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/57,58\" class=\"abstract_t\">57,58</a>], and immunosuppressive therapy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/59-64\" class=\"abstract_t\">59-64</a>]. (See <a href=\"topic.htm?path=molecularly-targeted-therapy-for-metastatic-melanoma#H100472985\" class=\"medical medical_review\">&quot;Molecularly targeted therapy for metastatic melanoma&quot;, section on 'BRAF inhibition'</a> and <a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy#H11\" class=\"medical medical_review\">&quot;Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy&quot;, section on 'Squamoproliferative lesions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Chemical carcinogens </strong>&ndash;<strong> </strong>Exposure to chemical carcinogens, such as tar, pitch, polyaromatic hydrocarbons in mineral oils, and cigarette smoking may increase risk for KA [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/8,23,65\" class=\"abstract_t\">8,23,65</a>]. Smoking was associated with increased risk for solitary KA in a case-control study of 78 patients with KA and 199 controls; 69 versus 22 percent of subjects were smokers [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/8\" class=\"abstract_t\">8</a>]. A contributory effect of acid refined mineral oils is supported by a Swedish study that found higher than expected rates of KA on the hands or forearms of workers exposed to these substances [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/65\" class=\"abstract_t\">65</a>]. Concordant with an inciting effect of these particular oils, KAs were no longer detected after a switch to solvent-refined mineral oils, which contain much lower concentrations of polyaromatic hydrocarbons.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Human papillomavirus infection </strong>&ndash;<strong> </strong>Similar to cutaneous squamous cell carcinoma, the role of human papilloma virus (HPV) in KA is uncertain. Although multiple serotypes of HPV have been detected in lesions from immunocompetent and immunocompromised patients with KA, data are insufficient to confirm a causative association between KA and this ubiquitous virus [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/23,66-68\" class=\"abstract_t\">23,66-68</a>]. (See <a href=\"topic.htm?path=epidemiology-and-risk-factors-for-cutaneous-squamous-cell-carcinoma#H22\" class=\"medical medical_review\">&quot;Epidemiology and risk factors for cutaneous squamous cell carcinoma&quot;, section on 'HPV infection'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H5186472\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple clinical presentations of KA are described in the literature including solitary KA (the most common manifestation) and several less common variants characterized by isolated or multiple lesions (<a href=\"image.htm?imageKey=DERM%2F76410\" class=\"graphic graphic_table graphicRef76410 \">table 2</a>). </p><p class=\"headingAnchor\" id=\"H2295744\"><span class=\"h2\">Solitary keratoacanthoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Solitary KA usually, but not always, develops on sun-exposed areas of the skin [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/34\" class=\"abstract_t\">34</a>]. The face (especially the eyelids, nose, cheek, and lower lip), neck, hands, and arms are common sites for involvement [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. Findings of consistent sun damage (eg, dyspigmentation, telangiectasias, and atrophy) are often present in the surrounding skin. </p><p>Although solitary KA is classically described as a dome-shaped, bud-shaped, or berry-shaped 1 to 2 cm papule with a central keratinous plug, the appearance of lesions varies with the stage of lesion development (<a href=\"image.htm?imageKey=DERM%2F55042%7EDERM%2F81629%7EDERM%2F59593%7EDERM%2F73408%7EDERM%2F52368\" class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \">picture 1A-E</a>) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>]. Three phases characterize the evolution of KA: proliferation, maturation, and involution. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Proliferation </strong>&ndash; Proliferation, the first stage of KA development, is defined by rapid growth that may persist for up to six to eight weeks. The initial lesion is usually a small pink macule that subsequently takes on a papular quality and eventually forms a circumscribed nodule. The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>]. The center of the nodule typically demonstrates a prominent keratinous core. Removal of this core results in a crateriform appearance.</p><p/><p class=\"bulletIndent1\">Solitary KA typically grows to a diameter of 1 to 2 cm [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/29,69\" class=\"abstract_t\">29,69</a>]. Lesions that exceed 2 cm in size are classified as giant KAs (<a href=\"image.htm?imageKey=DERM%2F66180\" class=\"graphic graphic_picture graphicRef66180 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"#H15906018\" class=\"local\">'Clinical variants'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Maturation </strong>&ndash; In the maturation phase, growth ceases. The KA maintains the nodular or crateriform appearance but may begin to demonstrate signs of fragmentation [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9,34,70\" class=\"abstract_t\">9,34,70</a>]. This phase often lasts for several weeks to several months. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Involution </strong>&ndash; The involution stage is characterized by spontaneous lesion regression. This process often takes four to six weeks, but may take longer. During involution, the remaining central keratin plug is expelled. The tumor eventually completely resolves leaving an atrophic, often hypopigmented scar [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/71,72\" class=\"abstract_t\">71,72</a>].</p><p/><p>The time course for lesions to proceed through the three phases is usually around four to nine months [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2,9,73\" class=\"abstract_t\">2,9,73</a>]. However, some KAs persist for greater than one year, complicating the clinical distinction of these lesions from cutaneous squamous cell carcinoma. (See <a href=\"topic.htm?path=keratoacanthoma-management-and-prognosis#H770593\" class=\"medical medical_review\">&quot;Keratoacanthoma: Management and prognosis&quot;, section on 'Deferring therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H15906018\"><span class=\"h2\">Clinical variants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major clinical variants of solitary KA include giant KA, subungual KA, mucosal KA, and keratoacanthoma centrifugum marginatum (KCM). </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Giant KA </strong>&ndash;<strong> </strong>KAs can develop into large lesions, with diameters ranging from greater than 2 cm to up to 15 cm (<a href=\"image.htm?imageKey=DERM%2F66180\" class=\"graphic graphic_picture graphicRef66180 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/74-79\" class=\"abstract_t\">74-79</a>]. Such lesions are referred to as giant KAs. Giant KA has a predilection for the nose and eyelids [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/78\" class=\"abstract_t\">78</a>]. Although spontaneous resolution usually eventually occurs, these lesions can cause considerable cosmetic disfigurement via the destruction of underlying structures [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/76,80\" class=\"abstract_t\">76,80</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Subungual KA </strong>&ndash;<strong> </strong>Subungual KA develops on the nail beds and may present with pain, swelling, and inflammation [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/81,82\" class=\"abstract_t\">81,82</a>]. As with classic KA, lesions develop quickly. The thumbs, index fingers, and middle fingers are the most frequently affected digits [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. In addition, erosion of underlying bone is frequently evident on radiologic examination. Compared with classic KAs, spontaneous resolution is less likely to occur in this variant [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/82\" class=\"abstract_t\">82</a>]. &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mucosal KA </strong>&ndash; Rarely, KAs develop on mucosal surfaces. The oral mucosa, conjunctiva, genitalia, or nasal mucosa may be affected [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/7,9,83,84\" class=\"abstract_t\">7,9,83,84</a>]. Mucosal lesions may also be seen in patients with generalized eruptive keratoacanthomas of Grzybowski. (See <a href=\"#H2295938\" class=\"local\">'Multiple keratoacanthomas'</a> below.) Spontaneous resolution of mucosal lesions usually does not occur.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Keratoacanthoma centrifugum marginatum (KCM) </strong>&ndash;<strong> </strong>KCM is distinguished from giant KA by its prominent horizontal growth pattern. The lesion exhibits progressive peripheral growth accompanied by central involution. Lesions of KCM may reach diameters of 20 or more centimeters and may occur on the face, trunk, or extremities (<a href=\"image.htm?imageKey=DERM%2F73851\" class=\"graphic graphic_picture graphicRef73851 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>]. Spontaneous resolution is unlikely [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/85\" class=\"abstract_t\">85</a>]. </p><p/><p>In addition to these four major subtypes of solitary KA, other uncommon presentations have been described, including vulvar KA in women [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/86-90\" class=\"abstract_t\">86-90</a>] and KA within nevus sebaceous, a presentation primarily reported in children and young adults [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/91,92\" class=\"abstract_t\">91,92</a>].</p><p class=\"headingAnchor\" id=\"H2295938\"><span class=\"h2\">Multiple keratoacanthomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several named disorders may present with multiple KAs (<a href=\"image.htm?imageKey=DERM%2F50780\" class=\"graphic graphic_picture graphicRef50780 \">picture 4</a> and <a href=\"image.htm?imageKey=DERM%2F76410\" class=\"graphic graphic_table graphicRef76410 \">table 2</a>). The major disorders characterized by this presentation are multiple self-healing squamous epithelioma (MSSE) and generalized eruptive keratoacanthomas of Grzybowski. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Multiple self-healing squamous epithelioma (MSSE, Ferguson-Smith disease, OMIM #132800) </strong>&ndash;<strong> </strong>MSSE is an autosomal dominant disorder attributed to loss-of-function mutations in the transforming growth factor beta receptor 1 (TGFBR1 or ALK5) gene [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/53\" class=\"abstract_t\">53</a>]. TGFBR1 mutations may lead to defects in TGF-beta function that result in the deregulation of cell proliferation and migration. Most affected families are of Scottish origin. (See <a href=\"#H1923380\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\">Features of MSSE most frequently appear during adolescence or early adulthood, but may also first occur earlier or later in life [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9,93\" class=\"abstract_t\">9,93</a>]. Affected patients develop several KAs to hundreds of KAs that spontaneously resolve, often leaving deep, destructive scars [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/23\" class=\"abstract_t\">23</a>]. Sun-exposed areas are most frequently affected, but may not be the only sites of involvement. Exacerbation of this disorder has been reported following radiation therapy [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/49\" class=\"abstract_t\">49</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Generalized eruptive keratoacanthomas of Grzybowski </strong>&ndash;<strong> </strong>Generalized eruptive keratoacanthomas of Grzybowski is a rare, sporadic disorder characterized by the abrupt appearance of numerous KAs [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9,94,95\" class=\"abstract_t\">9,94,95</a>]. The disorder usually occurs between the fifth and seventh decades of life [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/96\" class=\"abstract_t\">96</a>]. </p><p/><p class=\"bulletIndent1\">Patients with generalized eruptive keratoacanthomas of Grzybowski abruptly develop hundreds to thousands of follicular-based 1 to 5 mm papules with central keratotic cores on the trunk and extremities [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/12\" class=\"abstract_t\">12</a>]. Palm, sole, genital, and mucosal involvement may also be present [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>]. Affected individuals may experience pruritus, ectropion due to eyelid involvement, and sclerodermoid changes of the face due to extensive involvement in this area [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2,9,23,97\" class=\"abstract_t\">2,9,23,97</a>]. </p><p/><p>A rare presentation of multiple KAs characterized by features of both MSSE and generalized eruptive keratoacanthomas of Grzybowski has been reported, and is referred to as multiple familial keratoacanthoma of Witten and Zak [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/94,98\" class=\"abstract_t\">94,98</a>]. Patients with the variant of Lynch syndrome known as Muir-Torre syndrome, a genetic autosomal dominant condition characterized by KA, sebaceous tumors, and visceral malignancies, may also present with several KAs [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/97,99-104\" class=\"abstract_t\">97,99-104</a>]. In addition, a clinical presentation characterized by the coexistence of prurigo nodules and multiple KAs on pruritic, actinically-damaged skin has been described in several patients [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/105\" class=\"abstract_t\">105</a>]. (See <a href=\"topic.htm?path=lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis#H5\" class=\"medical medical_review\">&quot;Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis&quot;, section on 'Muir-Torre and Turcot variants'</a>.)</p><p class=\"headingAnchor\" id=\"H772735\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although observation of lesions with clinical features consistent with KA from the proliferative phase through spontaneous resolution has been used by some clinicians to diagnose and manage KA [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/72\" class=\"abstract_t\">72</a>], this process typically takes at least several months, and the diagnosis remains in question until lesion regression. A major concern related to this approach is the misdiagnosis of cutaneous squamous cell carcinoma, a lesion with a relatively greater risk for metastasis and death. Due to the difficulty in clinically distinguishing KA from cutaneous squamous cell carcinoma, we biopsy and treat all lesions suspicious for KA. The recognition of both clinical and histopathologic features consistent with KA is used to make the diagnosis.</p><p class=\"headingAnchor\" id=\"H1564594\"><span class=\"h2\">Clinical assessment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical assessment of patients with lesions suspicious for KA should always involve obtaining a clear account of the lesion time course since a history of rapid growth within weeks favors this diagnosis. Patients should also be questioned regarding a history of prior similar lesions, sebaceous tumors, and visceral malignancies. These questions may help to identify the presence of a syndromic disorder. (See <a href=\"#H2295938\" class=\"local\">'Multiple keratoacanthomas'</a> above.)</p><p>Since extensive sun-exposure is likely a precipitating factor for KA as well as multiple other cutaneous tumors, careful examination of the entire skin surface should be performed. In addition, the incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome. (See <a href=\"topic.htm?path=muir-torre-syndrome\" class=\"medical medical_review\">&quot;Muir-Torre syndrome&quot;</a>.)</p><p>Dermoscopy may aid in clinically distinguishing KA from other lesions, but cannot reliably distinguish KA from SCC [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/106\" class=\"abstract_t\">106</a>]. White circles, keratin, blood spots, and white structureless zones are common dermoscopic findings in both KA and SCC. (See <a href=\"topic.htm?path=overview-of-dermoscopy\" class=\"medical medical_review\">&quot;Overview of dermoscopy&quot;</a> and <a href=\"topic.htm?path=dermoscopic-evaluation-of-skin-lesions\" class=\"medical medical_review\">&quot;Dermoscopic evaluation of skin lesions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H772753\"><span class=\"h2\">Performing the biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The recognition of the classic pathological architecture of KA is a key component of diagnosis, and thus, performing the appropriate biopsy procedure is crucial for accurate assessment. Whenever feasible, biopsies should involve removal of the entire lesion. </p><p>The preferred method for obtaining a biopsy specimen is an excisional biopsy extending into the subcutaneous fat. At least a 4 mm margin is usually taken when feasible to concurrently suffice for treatment. (See <a href=\"topic.htm?path=keratoacanthoma-management-and-prognosis#H380984\" class=\"medical medical_review\">&quot;Keratoacanthoma: Management and prognosis&quot;, section on 'First-line therapy'</a>.)</p><p>An alternative method for obtaining the tissue specimen is the performance of a deep shave biopsy (also known as a saucerization procedure) that removes the entire lesion and extends into the subcutaneous fat. Since improperly performed shave biopsies are often inadequate for diagnosis, shave biopsies of KA should only be performed by clinicians with extensive experience with the shave procedure [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2\" class=\"abstract_t\">2</a>]. Punch biopsies do not allow for the examination of the lesion architecture, and therefore, are not recommended. (See <a href=\"topic.htm?path=skin-biopsy-techniques#H5\" class=\"medical medical_review\">&quot;Skin biopsy techniques&quot;, section on 'Biopsy techniques'</a>.)</p><p>Removal of the entire lesion for diagnosis may be impossible in patients with giant lesions or keratoacanthoma centrifugum marginatum (KCM). In such cases, a fusiform incisional biopsy through the center of the lesion that includes a cross-section of the lesion (periphery and center) and extends into the underlying fat can be performed [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9,107\" class=\"abstract_t\">9,107</a>]. This provides a specimen that represents the lesion architecture without total removal of the lesion.</p><p class=\"headingAnchor\" id=\"H5186479\"><span class=\"h2\">Interpretation of the biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although no single histopathologic finding reliably confirms a diagnosis of KA, an overall picture of consistent histopathologic and clinical findings is used to support the diagnosis. The histopathological features that typically characterize KA include [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/32,108\" class=\"abstract_t\">32,108</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epidermal hyperplasia with large eosinophilic keratinocytes</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Central invagination with a keratotic core (this may be less evident in early stage lesions)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&quot;Lipping&quot; or &quot;buttressing&quot; of the epidermis over the peripheral rim of the central keratotic plug</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sharp demarcation between the tumor and the surrounding stroma</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mixed inflammatory infiltrate in the dermis</p><p/><p>The majority of keratinocytes in KA do not exhibit signs of atypia, and mitoses are not a prominent feature, though they may be observed in the deepest components of some lesions [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/32\" class=\"abstract_t\">32</a>]. Islands of tumor cells may be present underlying the main portion of the tumor. The tumor islands usually do not extend beyond the depth of the eccrine glands. </p><p>Aggressive features such as perineural invasion and intravascular involvement may be seen in a minority of specimens from lesions of KA, and have been used by some authors to support the classification of KA as a variant of cutaneous squamous cell carcinoma [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/29,109\" class=\"abstract_t\">29,109</a>]. The significance of perineural invasion, a negative prognostic factor in cutaneous squamous cell carcinoma, is unclear in KA. (See <a href=\"topic.htm?path=keratoacanthoma-management-and-prognosis#H1564345\" class=\"medical medical_review\">&quot;Keratoacanthoma: Management and prognosis&quot;, section on 'Metastasis'</a>.)</p><p class=\"headingAnchor\" id=\"H256623\"><span class=\"h3\">Differentiation from SCC</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Differentiating KA from cutaneous squamous cell carcinoma based upon histopathologic examination is challenging [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/30,32\" class=\"abstract_t\">30,32</a>]. An analysis of approximately 300 KAs and squamous cell carcinomas found that no histopathologic criterion was sufficiently sensitive or specific to reliably distinguish between these lesions [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/32\" class=\"abstract_t\">32</a>]. However, among the pathologic features typically ascribed to KA, the presence of an epithelial lip and a sharp outline between the tumor and stroma appeared to be the most useful factors for the diagnosis of KA. In contrast, the presence of ulceration, mitoses, and pleomorphism or anaplasia favored a diagnosis of squamous cell carcinoma.</p><p>Due to the lack of histopathologic features that definitively distinguish KA from squamous cell carcinoma, studies of specific biomarkers and genetic analyses have attempted to identify additional methods for differentiating these lesions [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/25,28,110-125\" class=\"abstract_t\">25,28,110-125</a>]. Promising examples include recognition of the labelling pattern of the cytolytic calcium channel receptor p2X<sub>7</sub>, a marker of apoptosis [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/25\" class=\"abstract_t\">25</a>], and the detection of specific chromosomal aberrations within these lesions [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/28\" class=\"abstract_t\">28</a>]. Further studies are necessary to determine whether these tests and other studies will be useful for diagnosis in the clinical setting.</p><p class=\"headingAnchor\" id=\"H256506\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of KA is broad and includes other nodular tumors and growths of the skin. The combination of a history of rapid growth, central keratotic crater formation, and consistent histopathologic findings are often helpful for distinguishing KA from other disorders. </p><p>As noted above, squamous cell carcinoma is the most difficult disorder to distinguish from KA due to the multiple clinical and histopathologic similarities between these lesions. Examples of additional lesions to consider in the differential diagnosis of solitary KA include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nodular basal cell carcinoma (<a href=\"image.htm?imageKey=DERM%2F65704\" class=\"graphic graphic_picture graphicRef65704 \">picture 5</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Merkel cell carcinoma (<a href=\"image.htm?imageKey=DERM%2F70535\" class=\"graphic graphic_picture graphicRef70535 \">picture 6</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prurigo nodule (<a href=\"image.htm?imageKey=DERM%2F53475\" class=\"graphic graphic_picture graphicRef53475 \">picture 7</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Giant molluscum contagiosum (<a href=\"image.htm?imageKey=DERM%2F62590\" class=\"graphic graphic_picture graphicRef62590 \">picture 8</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Deep fungal infection (eg, sporotrichosis) (<a href=\"image.htm?imageKey=ID%2F74515\" class=\"graphic graphic_picture graphicRef74515 \">picture 9</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nodular Kaposi&rsquo;s sarcoma (<a href=\"image.htm?imageKey=DERM%2F54707\" class=\"graphic graphic_picture graphicRef54707 \">picture 10</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous metastases [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/126,127\" class=\"abstract_t\">126,127</a>]</p><p/><p>The combination of clinical assessment and biopsies are also useful for narrowing the differential diagnosis for other presentations of KA. The possibility of paronychia, periungual squamous cell carcinoma, viral warts, and subungual tumors associated with incontinentia pigmenti [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/128\" class=\"abstract_t\">128</a>] should be considered in patients with lesions suspicious for subungual KA. In addition, the clinical appearance of KCM may resemble giant porokeratosis of Mibelli, a deep fungal infection, or halogenoderma [<a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/129\" class=\"abstract_t\">129</a>]. In patients with suspected multiple KA syndromes, the possibility of other disorders that may present with widespread nodular lesions, including prurigo nodularis and perforating disorders (eg, Kyrle&rsquo;s disease), should be considered.</p><p class=\"headingAnchor\" id=\"H256997\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Keratoacanthoma (KA) is a cutaneous tumor that most commonly occurs in middle-aged and elderly individuals with fair skin. Controversy exists over whether KA represents a distinct disease entity or a variant of cutaneous squamous cell carcinoma. (See <a href=\"#H5186451\" class=\"local\">'Epidemiology'</a> above and <a href=\"#H1923197\" class=\"local\">'Relationship with squamous cell carcinoma'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pathogenesis of KA is poorly understood. Factors that influence epidermal cell proliferation, cell adhesion, cell survival, and apoptosis have been identified as potential contributors to these lesions. (See <a href=\"#H1923751\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk factors associated with KA include fair skin, exposure to ultraviolet radiation or chemical carcinogens, genetic abnormalities, and certain medications. The role of human papillomavirus in KA remains uncertain. (See <a href=\"#H1923380\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Solitary KA is the most common manifestation of KA. Lesions are usually 1 to 2 cm in diameter and are most commonly found on sun-exposed skin (<a href=\"image.htm?imageKey=DERM%2F55042%7EDERM%2F81629%7EDERM%2F59593%7EDERM%2F73408%7EDERM%2F52368\" class=\"graphic graphic_picture graphicRef55042 graphicRef81629 graphicRef59593 graphicRef73408 graphicRef52368 \">picture 1A-E</a>). Solitary KAs undergo three phases of evolution: a proliferative period of several weeks, a maturation phase that may persist for several months, and eventual lesion regression. (See <a href=\"#H2295744\" class=\"local\">'Solitary keratoacanthoma'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A variety of additional variants of KA have been described, including giant KA (<a href=\"image.htm?imageKey=DERM%2F66180\" class=\"graphic graphic_picture graphicRef66180 \">picture 2</a>), subungual KA, mucosal KA, and keratoacanthoma centrifugum marginatum. KAs may also present as a feature of multiple KA syndromes, such as multiple self-healing squamous epithelioma (Ferguson-Smith disease) and generalized eruptive keratoacanthomas of Grzybowski. In addition, the Muir-Torre variant of Lynch syndrome may present with KA, sebaceous tumors, and visceral cancer. (See <a href=\"#H15906018\" class=\"local\">'Clinical variants'</a> above and <a href=\"#H2295938\" class=\"local\">'Multiple keratoacanthomas'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We biopsy lesions of KA due to the difficulty in clinically distinguishing KA from squamous cell carcinoma. Although histopathologic findings cannot definitively differentiate these lesions, the combined assessment of clinical and histopathologic findings is useful for determining the appropriate diagnosis. (See <a href=\"#H772735\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete removal of the lesion via surgical excision is the preferred biopsy procedure for lesions suspicious for KA. Shave biopsies may be inadequate if performed with improper technique and should only be performed by clinicians experienced in this procedure. (See <a href=\"#H772753\" class=\"local\">'Performing the biopsy'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">Kwiek B, Schwartz RA. Keratoacanthoma (KA): An update and review. J Am Acad Dermatol 2016; 74:1220.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Schwartz RA. Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg 2004; 30:326.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Vergilis-Kalner IJ, Kriseman Y, Goldberg LH. Keratoacanthomas: overview and comparison between Houston and minneapolis experiences. J Drugs Dermatol 2010; 9:117.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Buescher L, DeSpain JD, Diaz-Arias AA, Roller JA. Keratoacanthoma arising in an organoid nevus during childhood: case report and literature review. Pediatr Dermatol 1991; 8:117.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993; 15:332.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Maruani A, Michenet P, Lagasse JP, et al. [Keratoacanthoma of the anal margin]. Gastroenterol Clin Biol 2004; 28:906.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Perdig&atilde;o FB, Pierre-Filho Pde T, Natalino RJ, et al. Conjunctival keratoacanthoma. Rev Hosp Clin Fac Med Sao Paulo 2004; 59:135.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Miot HA, Miot LD, da Costa AL, et al. Association between solitary keratoacanthoma and cigarette smoking: a case-control study. Dermatol Online J 2006; 12:2.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Schwartz RA. Keratoacanthoma. J Am Acad Dermatol 1994; 30:1.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Dufresne RG, Marrero GM, Robinson-Bostom L. Seasonal presentation of keratoacanthomas in Rhode Island. Br J Dermatol 1997; 136:227.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Yoshikawa K, Katagata Y, Kondo S. Relative amounts of keratin 17 are higher than those of keratin 16 in hair-follicle-derived tumors in comparison with nonfollicular epithelial skin tumors. J Invest Dermatol 1995; 104:396.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Ko CJ. Keratoacanthoma: facts and controversies. Clin Dermatol 2010; 28:254.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Cao Z, Yoon JH, Nam SW, et al. Mutational analysis of the HIPK2 gene in keratoacanthoma and squamous cell carcinoma of the skin. APMIS 2011; 119:399.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Batinac T, Zamolo G, Coklo M, et al. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma. Pathol Res Pract 2006; 202:599.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Corominas M, Sloan SR, Leon J, et al. ras activation in human tumors and in animal model systems. Environ Health Perspect 1991; 93:19.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Corominas M, Leon J, Kamino H, et al. Oncogene involvement in tumor regression: H-ras activation in the rabbit keratoacanthoma model. Oncogene 1991; 6:645.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Tataroglu C, Karabacak T, Apa DD. Beta-catenin and CD44 expression in keratoacanthoma and squamous cell carcinoma of the skin. Tumori 2007; 93:284.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">Ribeiro D, Narikawa S, Marques ME. Expression of apoptotic and cell proliferation regulatory proteins in keratoacanthomas and squamous cell carcinomas of the skin. Pathol Res Pract 2008; 204:97.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">Batinac T, Zamolo G, Brumini G, et al. Cell apoptosis as assessed by M30 expression in keratoacanthoma and squamous cell carcinoma. Coll Antropol 2008; 32:499.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Tan KB, Lee YS. Immunoexpression of Bcl-x in squamous cell carcinoma and keratoacanthoma: differences in pattern and correlation with pathobiology. Histopathology 2009; 55:338.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Batinac T, Zamolo G, Coklo M, Hadzisejdic I. Possible key role of granzyme B in keratoacanthoma regression. Med Hypotheses 2006; 66:1129.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Hu W, Cook T, Oh CW, Penneys NS. Expression of the cyclin-dependent kinase inhibitor p27 in keratoacanthoma. J Am Acad Dermatol 2000; 42:473.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol 2007; 46:671.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Weedon D. Keratoacanthoma: a personal perspective. Curr Diagn Pathol 2003; 9:259.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Slater M, Barden JA. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology 2005; 47:170.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Waring AJ, Takata M, Rehman I, Rees JL. Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma. Br J Cancer 1996; 73:649.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Weedon D, Malo J, Brooks D, Williamson R. Keratoacanthoma: is it really a variant of squamous cell carcinoma? ANZ J Surg 2010; 80:129.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol 2006; 126:2308.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Beham A, Regauer S, Soyer HP, Beham-Schmid C. Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol 1998; 5:269.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Ackerman AB. Squamous-cell carcinoma vs. keratoacanthoma. J Dermatol Surg Oncol 1982; 8:418.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Ackerman CC. Keratoacanthomas: a new classification based on morphologic findings and on anatomic site. Dermatopathol Pract Concept 2001; 7:7.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999; 199:208.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Poleksic S, Yeung KY. Rapid development of keratoacanthoma and accelerated transformation into squamous cell carcinoma of the skin: a mutagenic effect of polychemotherapy in a patient with Hodgkin's disease? Cancer 1978; 41:12.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">S&aacute;nchez Yus E, Sim&oacute;n P, Requena L, et al. Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant. Am J Dermatopathol 2000; 22:305.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Heyl T, Morrison JG. Keratoacanthoma in a Bantu patient. Br J Dermatol 1975; 93:699.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Sullivan JJ. Keratoacanthoma: the Australian experience. Australas J Dermatol 1997; 38 Suppl 1:S36.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Chuang TY, Reizner GT, Elpern DJ, et al. Non-melanoma skin cancer and keratoacanthoma in Filipinos: an incidence report from Kauai, Hawaii. Int J Dermatol 1993; 32:717.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Reizner GT, Chuang TY, Elpern DJ, et al. Keratoacanthoma in Japanese Hawaiians in Kauai, Hawaii. Int J Dermatol 1995; 34:851.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Chuang TY, Heinrich LA, Schultz MD, et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992; 26:173.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Pattee SF, Silvis NG. Keratoacanthoma developing in sites of previous trauma: a report of two cases and review of the literature. J Am Acad Dermatol 2003; 48:S35.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Janik JP, Bang RH. Traumatic keratoacanthoma arising in a 15-year-old boy following a motor vehicle accident. Pediatr Dermatol 2006; 23:448.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Epstein EH Jr, Epstein EH. Keratoacanthoma recurrent after surgical excision. J Dermatol Surg Oncol 1978; 4:524.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Goldberg LH, Silapunt S, Beyrau KK, et al. Keratoacanthoma as a postoperative complication of skin cancer excision. J Am Acad Dermatol 2004; 50:753.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Kimyai-Asadi A, Shaffer C, Levine VJ, Jih MH. Keratoacanthoma arising from an excisional surgery scar. J Drugs Dermatol 2004; 3:193.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Bunker CB. Keratoacanthoma, trauma, and cryotherapy. Dermatol Surg 2011; 37:1709.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">Kaptanoglu AF, Kutluay L. Keratoacanthoma developing in previous cryotherapy site for solar keratosis. J Eur Acad Dermatol Venereol 2006; 20:197.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">Gewirtzman A, Meirson DH, Rabinovitz H. Eruptive keratoacanthomas following carbon dioxide laser resurfacing. Dermatol Surg 1999; 25:666.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Mamelak AJ, Goldberg LH, Marquez D, et al. Eruptive keratoacanthomas on the legs after fractional photothermolysis: report of two cases. Dermatol Surg 2009; 35:513.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">Robertson SJ, Bashir SJ, Pichert G, et al. Severe exacerbation of multiple self-healing squamous epithelioma (Ferguson-Smith disease) with radiotherapy, which was successfully treated with acitretin. Clin Exp Dermatol 2010; 35:e100.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Chowdhury RK, Padhi T, Das GS. Keratoacanthoma of the conjunctiva complicating xeroderma pigmentosum. Indian J Dermatol Venereol Leprol 2005; 71:430.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Bhutto AM, Shaikh A, Nonaka S. Incidence of xeroderma pigmentosum in Larkana, Pakistan: a 7-year study. Br J Dermatol 2005; 152:545.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">Tennstedt D, Lachapelle JM. [Keratoacanthomas and xeroderma pigmentosum (author's transl)]. Ann Dermatol Venereol 1977; 104:98.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">Goudie DR, D'Alessandro M, Merriman B, et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet 2011; 43:365.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18:314.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/57\" class=\"nounderline abstract_t\">Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009; 35:1766.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7:20.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">Dessoukey MW, Omar MF, Abdel-Dayem H. Eruptive keratoacanthomas associated with immunosuppressive therapy in a patient with systemic lupus erythematosus. J Am Acad Dermatol 1997; 37:478.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/60\" class=\"nounderline abstract_t\">Euvrard S, Chardonnet Y, Hermier C, et al. [Warts and epidermoid carcinoma after renal transplantation]. Ann Dermatol Venereol 1989; 116:201.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Jacobsson S, Linell F, Rausing A. Florid keratoacanthomas in a kidney transplant recipient. Case report. Scand J Plast Reconstr Surg 1974; 8:243.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">Lowry WS, Clark DA, Hannemann JH. Skin cancer and immunosuppression. Lancet 1972; 1:1290.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/63\" class=\"nounderline abstract_t\">Walder BK, Robertson MR, Jeremy D. Skin cancer and immunosuppression. Lancet 1971; 2:1282.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/64\" class=\"nounderline abstract_t\">Washington CV Jr, Mikhail GR. Eruptive keratoacanthoma en plaque in an immunosuppressed patient. J Dermatol Surg Oncol 1987; 13:1357.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/65\" class=\"nounderline abstract_t\">J&auml;rvholm B, Fast K, Lavenius B, Tomsic P. Exposure to cutting oils and its relation to skin tumors and premalignant skin lesions on the hands and forearms. Scand J Work Environ Health 1985; 11:365.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/66\" class=\"nounderline abstract_t\">Viviano E, Sorce M, Mantegna M. Solitary keratoacanthomas in immunocompetent patients: no detection of papillomavirus DNA by polymerase chain reaction. New Microbiol 2001; 24:295.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/67\" class=\"nounderline abstract_t\">Forslund O, DeAngelis PM, Beigi M, et al. Identification of human papillomavirus in keratoacanthomas. J Cutan Pathol 2003; 30:423.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/68\" class=\"nounderline abstract_t\">Hsi ED, Svoboda-Newman SM, Stern RA, et al. Detection of human papillomavirus DNA in keratoacanthomas by polymerase chain reaction. Am J Dermatopathol 1997; 19:10.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/69\" class=\"nounderline abstract_t\">Kwittken J. A histologic chronology of the clinical course of the keratocarcinoma (so-called keratoacanthoma). Mt Sinai J Med 1975; 42:127.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/70\" class=\"nounderline abstract_t\">Hundeiker M. [Clinical variations of keratoacanthomas]. Z Hautkr 1978; 53:563.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/71\" class=\"nounderline abstract_t\">Seifert A, Nasemann T. [Keratoacanthoma and its clinical variants. Review of the literature and histopathologic analysis of 90 cases]. Hautarzt 1989; 40:189.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/72\" class=\"nounderline abstract_t\">Griffiths RW. Keratoacanthoma observed. Br J Plast Surg 2004; 57:485.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/73\" class=\"nounderline abstract_t\">Clausen OP, Beigi M, Bolund L, et al. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol 2002; 119:1367.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/74\" class=\"nounderline abstract_t\">Hofer SO, Jackson IT. Self-involution of giant keratoacanthoma on the tip of the nose. Plast Reconstr Surg 2004; 113:765.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/75\" class=\"nounderline abstract_t\">Moriyama M, Watanabe T, Sakamoto N, et al. A case of giant keratoacanthoma of the auricle. Auris Nasus Larynx 2000; 27:185.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/76\" class=\"nounderline abstract_t\">Webb AJ, Ghadially FN. Massive or giant keratoacanthoma. J Pathol Bacteriol 1966; 91:505.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/77\" class=\"nounderline abstract_t\">Saito M, Sasaki Y, Yamazaki N, Shimizu H. Self-involution of giant keratoacanthoma on the tip of the nose. Plast Reconstr Surg 2003; 111:1561.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/78\" class=\"nounderline abstract_t\">Browne F, O'Connell M, Merchant W, et al. Spontaneous resolution of a giant keratoacanthoma penetrating through the nose. Clin Exp Dermatol 2011; 36:369.</a></li><li class=\"breakAll\">Cerroni L, Kerl H. Keratoacanthoma. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill, 2008. Vol 1, p.1049.</li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/80\" class=\"nounderline abstract_t\">Leonard AL, Hanke CW. Treatment of giant keratoacanthoma with intralesional 5-fluorouracil. J Drugs Dermatol 2006; 5:454.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/81\" class=\"nounderline abstract_t\">Sinha A, Marsh R, Langtry J. Spontaneous regression of subungual keratoacanthoma with reossification of underlying distal lytic phalynx. Clin Exp Dermatol 2005; 30:20.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/82\" class=\"nounderline abstract_t\">Oliwiecki S, Peachey RD, Bradfield JW, et al. Subungual keratoacanthoma--a report of four cases and review of the literature. Clin Exp Dermatol 1994; 19:230.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/83\" class=\"nounderline abstract_t\">Janette A, Pecaro B, Lonergan M, Lingen MW. Solitary intraoral keratoacanthoma: report of a case. J Oral Maxillofac Surg 1996; 54:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/84\" class=\"nounderline abstract_t\">Freedman PD, Kerpel SM, Begel H, Lumerman H. Solitary intraoral keratoacanthoma. Report of a case. Oral Surg Oral Med Oral Pathol 1979; 47:74.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/85\" class=\"nounderline abstract_t\">Attili Sk, Attili VR. Keratoacanthoma centrifugum marginatum arising in vitiligo: a case report. Dermatol Online J 2006; 12:18.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/86\" class=\"nounderline abstract_t\">Eversole LR, Leider AS, Alexander G. Intraoral and labial keratoacanthoma. Oral Surg Oral Med Oral Pathol 1982; 54:663.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/87\" class=\"nounderline abstract_t\">Hood AF, Lumadue J. Benign vulvar tumors. Dermatol Clin 1992; 10:371.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/88\" class=\"nounderline abstract_t\">Rhatigan RM, Nuss RC. Keratoacanthoma of the vulva. Gynecol Oncol 1985; 21:118.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/89\" class=\"nounderline abstract_t\">Ozkan F, Bilgi&ccedil; R, Cesur S. Vulvar keratoacanthoma. APMIS 2006; 114:562.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/90\" class=\"nounderline abstract_t\">Chen W, Koenig C. Vulvar keratoacanthoma: a report of two cases. Int J Gynecol Pathol 2004; 23:284.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/91\" class=\"nounderline abstract_t\">Ujiie H, Kato N, Natsuga K, Tomita Y. Keratoacanthoma developing on nevus sebaceous in a child. J Am Acad Dermatol 2007; 56:S57.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/92\" class=\"nounderline abstract_t\">Ginzburg MA, Kol'tsova IA, Stepenski&#301; DB, Fedorova GIa. [Course of pulmonary tuberculosis in patients with diabetes mellitus according to roentgenological data]. Probl Tuberk 1977; :30.</a></li><li class=\"breakAll\">http://us-east.omim.org/entry/132800 (Accessed on January 29, 2012).</li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/94\" class=\"nounderline abstract_t\">Feldman RJ, Maize JC. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol 2007; 46:77.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/95\" class=\"nounderline abstract_t\">Kavanagh GM, Marshman G, Hanna MM. A case of Grzybowski's generalized eruptive keratoacanthomas. Australas J Dermatol 1995; 36:83.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/96\" class=\"nounderline abstract_t\">Lu PD, Lee A, Cassetty CT, et al. Generalized eruptive keratoacanthomas of Grzybowski. Dermatol Online J 2009; 15:6.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/97\" class=\"nounderline abstract_t\">Wee SA. Multiple eruptive keratoacanthomas, de novo. Dermatol Online J 2004; 10:19.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/98\" class=\"nounderline abstract_t\">Agarwal M, Chander R, Karmakar S, Walia R. Multiple familial keratoacanthoma of Witten and Zak - A report of three siblings. Dermatology 1999; 198:396.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/99\" class=\"nounderline abstract_t\">Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005; 6:980.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/100\" class=\"nounderline abstract_t\">Yoshikawa R, Utsunomiya J. [Muir-Torre syndrome]. Nihon Rinsho 1995; 53:2803.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/101\" class=\"nounderline abstract_t\">Ponti G, Ponz de Leon M, Losi L, et al. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families. Br J Dermatol 2005; 152:1335.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/102\" class=\"nounderline abstract_t\">Akhtar S, Oza KK, Khan SA, Wright J. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 1999; 41:681.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/103\" class=\"nounderline abstract_t\">Hartig C, Stieler W, Stadler R. [Muir-Torre syndrome. Diagnostic criteria and review of the literature]. Hautarzt 1995; 46:107.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/104\" class=\"nounderline abstract_t\">Nishizawa A, Nakanishi Y, Sasajima Y, et al. Muir-torre syndrome with intriguing squamous lesions: a case report and review of the literature. Am J Dermatopathol 2006; 28:56.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/105\" class=\"nounderline abstract_t\">Wu TP, Miller K, Cohen DE, Stein JA. Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skin. J Am Acad Dermatol 2013; 69:426.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/106\" class=\"nounderline abstract_t\">Rosendahl C, Cameron A, Argenziano G, et al. Dermoscopy of squamous cell carcinoma and keratoacanthoma. Arch Dermatol 2012; 148:1386.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/107\" class=\"nounderline abstract_t\">Popkin GL, Brodie SJ, Hyman AB, et al. A technique of biopsy recommended for keratoacanthomas. Arch Dermatol 1966; 94:191.</a></li><li class=\"breakAll\">Weedon D. Tumors of the epidermis. In: Weedon's Skin Pathology, 3rd Ed, Elsevier Limited, 2010. p.667.</li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/109\" class=\"nounderline abstract_t\">Gottfarstein-Maruani A, Michenet P, Kerdraon R, et al. [Keratoacanthoma: two cases with intravascular spread]. Ann Pathol 2003; 23:438.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/110\" class=\"nounderline abstract_t\">Melendez ND, Smoller BR, Morgan M. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas. Mod Pathol 2003; 16:8.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/111\" class=\"nounderline abstract_t\">Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001; 158:1633.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/112\" class=\"nounderline abstract_t\">Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994; 130:181.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/113\" class=\"nounderline abstract_t\">Cain CT, Niemann TH, Argenyi ZB. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors. Am J Dermatopathol 1995; 17:324.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/114\" class=\"nounderline abstract_t\">Putti TC, Teh M, Lee YS. Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers. Mod Pathol 2004; 17:468.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/115\" class=\"nounderline abstract_t\">Sk&aacute;lov&aacute; A, Michal M. Patterns of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of the skin. Immunohistochemical study using the MIB 1 antibody in formalin-fixed paraffin sections. Am J Dermatopathol 1995; 17:332.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/116\" class=\"nounderline abstract_t\">Ho T, Horn T, Finzi E. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas. Arch Dermatol 1991; 127:1167.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/117\" class=\"nounderline abstract_t\">Kaabipour E, Haupt HM, Stern JB, et al. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. Arch Pathol Lab Med 2006; 130:69.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/118\" class=\"nounderline abstract_t\">Kuivanen TT, Jeskanen L, Kyll&ouml;nen L, et al. Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas. Mod Pathol 2006; 19:1203.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/119\" class=\"nounderline abstract_t\">Tran TA, Ross JS, Sheehan CE, Carlson JA. Comparison of oncostatin M expression in keratoacanthoma and squamous cell carcinoma. Mod Pathol 2000; 13:427.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/120\" class=\"nounderline abstract_t\">Kannon G, Park HK. Utility of peanut agglutinin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma. Am J Dermatopathol 1990; 12:31.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/121\" class=\"nounderline abstract_t\">Ariano MC, Wiley EL, Ariano L, et al. H, peanut lectin receptor, and carcinoembryonic antigen distribution in keratoacanthomas, squamous dysplasias, and carcinomas of skin. J Dermatol Surg Oncol 1985; 11:1076.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/122\" class=\"nounderline abstract_t\">Mukunyadzi P, Sanderson RD, Fan CY, Smoller BR. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma. Mod Pathol 2002; 15:45.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/123\" class=\"nounderline abstract_t\">Biesterfeld S, Josef J. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry. Anticancer Res 2002; 22:3019.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/124\" class=\"nounderline abstract_t\">Asch PH, Basset P, Roos M, et al. Expression of stromelysin 3 in keratoarcanthoma and squamous cell carcinoma. Am J Dermatopathol 1999; 21:146.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/125\" class=\"nounderline abstract_t\">Corbal&aacute;n-V&eacute;lez R, Mart&iacute;nez-Barba E, L&oacute;pez-Poveda MJ, et al. [The value of laminin-322 staining in distinguishing between keratoacanthoma, keratoacanthoma with areas of squamous cell carcinoma, and crateriform squamous cell carcinoma]. Actas Dermosifiliogr 2012; 103:308.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/126\" class=\"nounderline abstract_t\">Riahi RR, Cohen PR. Clinical manifestations of cutaneous metastases: a review with special emphasis on cutaneous metastases mimicking keratoacanthoma. Am J Clin Dermatol 2012; 13:103.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/127\" class=\"nounderline abstract_t\">Reich A, Kobierzycka M, Wo&#378;niak Z, et al. Keratoacanthoma-like cutaneous metastasis of lung cancer: a learning point. Acta Derm Venereol 2006; 86:459.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/128\" class=\"nounderline abstract_t\">Montes CM, Maize JC, Guerry-Force ML. Incontinentia pigmenti with painful subungual tumors: a two-generation study. J Am Acad Dermatol 2004; 50:S45.</a></li><li><a href=\"https://www.uptodate.com/contents/keratoacanthoma-epidemiology-risk-factors-and-diagnosis/abstract/129\" class=\"nounderline abstract_t\">Divers AK, Correale D, Lee JB. Keratoacanthoma centrifugum marginatum: a diagnostic and therapeutic challenge. Cutis 2004; 73:257.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13718 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H256997\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H5186444\" id=\"outline-link-H5186444\">INTRODUCTION</a></li><li><a href=\"#H5186451\" id=\"outline-link-H5186451\">EPIDEMIOLOGY</a></li><li><a href=\"#H1923751\" id=\"outline-link-H1923751\">PATHOGENESIS</a></li><li><a href=\"#H1923197\" id=\"outline-link-H1923197\">RELATIONSHIP WITH SQUAMOUS CELL CARCINOMA</a></li><li><a href=\"#H1923380\" id=\"outline-link-H1923380\">RISK FACTORS</a></li><li><a href=\"#H5186472\" id=\"outline-link-H5186472\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H2295744\" id=\"outline-link-H2295744\">Solitary keratoacanthoma</a></li><li><a href=\"#H15906018\" id=\"outline-link-H15906018\">Clinical variants</a></li><li><a href=\"#H2295938\" id=\"outline-link-H2295938\">Multiple keratoacanthomas</a></li></ul></li><li><a href=\"#H772735\" id=\"outline-link-H772735\">DIAGNOSIS</a><ul><li><a href=\"#H1564594\" id=\"outline-link-H1564594\">Clinical assessment</a></li><li><a href=\"#H772753\" id=\"outline-link-H772753\">Performing the biopsy</a></li><li><a href=\"#H5186479\" id=\"outline-link-H5186479\">Interpretation of the biopsy</a><ul><li><a href=\"#H256623\" id=\"outline-link-H256623\">- Differentiation from SCC</a></li></ul></li><li><a href=\"#H256506\" id=\"outline-link-H256506\">Differential diagnosis</a></li></ul></li><li><a href=\"#H256997\" id=\"outline-link-H256997\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13718|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/55042\" class=\"graphic graphic_picture\">- Keratoacanthoma - face</a></li><li><a href=\"image.htm?imageKey=DERM/81629\" class=\"graphic graphic_picture\">- Keratoacanthoma on ear</a></li><li><a href=\"image.htm?imageKey=DERM/59593\" class=\"graphic graphic_picture\">- Keratoacanthoma on hand</a></li><li><a href=\"image.htm?imageKey=DERM/73408\" class=\"graphic graphic_picture\">- Solitary keratoacanthoma</a></li><li><a href=\"image.htm?imageKey=DERM/52368\" class=\"graphic graphic_picture\">- Keratoacanthoma on eyelid</a></li><li><a href=\"image.htm?imageKey=DERM/66180\" class=\"graphic graphic_picture\">- Giant keratoacanthoma on nose</a></li><li><a href=\"image.htm?imageKey=DERM/73851\" class=\"graphic graphic_picture\">- Keratoacanthoma centrifugum marginatum</a></li><li><a href=\"image.htm?imageKey=DERM/50780\" class=\"graphic graphic_picture\">- Multiple keratoacanthomas</a></li><li><a href=\"image.htm?imageKey=DERM/65704\" class=\"graphic graphic_picture\">- Nodular basal cell carcinoma</a></li><li><a href=\"image.htm?imageKey=DERM/70535\" class=\"graphic graphic_picture\">- Merkel cell carcinoma</a></li><li><a href=\"image.htm?imageKey=DERM/53475\" class=\"graphic graphic_picture\">- Prurigo nodularis 1</a></li><li><a href=\"image.htm?imageKey=DERM/62590\" class=\"graphic graphic_picture\">- Giant molluscum contagiosum</a></li><li><a href=\"image.htm?imageKey=ID/74515\" class=\"graphic graphic_picture\">- Fixed cutaneous sporotrichosis</a></li><li><a href=\"image.htm?imageKey=DERM/54707\" class=\"graphic graphic_picture\">- Classic Kaposi sarcoma - nodules</a></li></ul></li><li><div id=\"DERM/13718|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PC/60541\" class=\"graphic graphic_table\">- Fitzpatrick skin phototypes</a></li><li><a href=\"image.htm?imageKey=DERM/76410\" class=\"graphic graphic_table\">- Multiple keratoacanthoma clinical variants</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-cutaneous-squamous-cell-carcinoma-scc\" class=\"medical medical_review\">Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermoscopic-evaluation-of-skin-lesions\" class=\"medical medical_review\">Dermoscopic evaluation of skin lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-risk-factors-for-cutaneous-squamous-cell-carcinoma\" class=\"medical medical_review\">Epidemiology and risk factors for cutaneous squamous cell carcinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=keratoacanthoma-management-and-prognosis\" class=\"medical medical_review\">Keratoacanthoma: Management and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=molecularly-targeted-therapy-for-metastatic-melanoma\" class=\"medical medical_review\">Molecularly targeted therapy for metastatic melanoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=muir-torre-syndrome\" class=\"medical medical_review\">Muir-Torre syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-dermoscopy\" class=\"medical medical_review\">Overview of dermoscopy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=skin-biopsy-techniques\" class=\"medical medical_review\">Skin biopsy techniques</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-genodermatoses\" class=\"medical medical_review\">The genodermatoses</a></li></ul></div></div>","javascript":null}